Levulan Kerastick
PreclinicalSmall molecule
Levulan Kerastick is one of 17 small molecule programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Cutaneous Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Taxol
TevaApproved
Libtayo
RegeneronPhase 3
Rayos
RRoxane Laboratories
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Keytruda
Merck & Co.Phase 3
UNLOXCYT
Sun Pharmaceutical Industries, Inc.Approved
Intismeran Autogene
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Erbitux
IImclone
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levulan Kerastick. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRhode Island Hospital